louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01129752: Mothers With a History of Depression and Their 10-14 Year Old Daughters
Official title: The Neural Correlates of Mood and Cognitive Bias in a Population at Risk for Depression: Maternal Cognitive and Emotional Functioning
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Depression
Depressive Disorder, Major
Lead sponsor: Stanford University
Sponsor class: OTHER
Collaborators: name: National Institute of Mental Health (NIMH)
First posted: 2010-05-25
Enrollment: 240
Sex: FEMALE
Minimum age (years): 9
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Eligible mothers must read and speak English fluently and have a child between the ages of 9 and 15 years old. Mothers must either have no history of psychopathology or have a history of depression during their child's lifetime.

Brief summary: The purpose of this study is to investigate risk factors associated with depression and how such factors might be transmitted cross-generationally. The investigators are conducting an integrative assessment of emotion regulation and stress reactivity in a group of mothers with and without a history of depression and their daughters.

Detailed description: The purpose of this study is to investigate risk factors associated with depression and how such factors might be transmitted cross-generationally. We are conducting an integrative assessment of emotion regulation and stress reactivity in a group of mothers with and without a history of depression and their daughters. We use a range of methodologies to evaluate these processes, including self-report measures, information-processing performance, HPA-axis functioning and reactivity, and neural responses to emotional stimuli following exposure to stressful experiences.

Eligibility criteria: Inclusion Criteria:

* Eligible mothers must read and speak English fluently and have a child between the ages of 9 and 15 years old.
* Mothers must either have no history of psychopathology or have a history of depression during their child's lifetime.

Exclusion Criteria:

* Eligible mothers cannot:

  * currently be in treatment for drug or alcohol abuse
  * have significant symptomatology related to psychopathology outside of depression
  * have a medical history of neurological injury or impairment.
* Mothers who meet the requirements for inclusion in the control group must not have a history of any Axis I disorder.

Primary outcomes:
measure: Onset of depression
timeFrame: 18 months
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University Department of Psychology
state: California
city: Stanford
country: United States
facility: Stanford University School of Medicine
state: California
Study officials:
affiliation: Stanford University Department of Psychology
name: Ian H Gotlib, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05922852: Effect of Novel Antidiabetic Drug Combined With Angiotensin Receptor/Neprilysin Inhibitor on Urinary Protein
Official title: the Effect of Novel Antidiabetic Drug Combined With Angiotensin Receptor/Neprilysin Inhibitor Over Monotherapy on Urinary Protein in Patients With Type 2 Diabetes
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Type 2 Diabetes
Antidiabetic Drugs
Lead sponsor: Peking University Third Hospital
Sponsor class: OTHER
First posted: 2023-06-28
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients with type 2 diabetes mellitus

Brief summary: The purpose of this study is to determine whether the combination of SGLT2i and ARNI in type 2 diabetic patients with combined albuminuria could reduce urinary protein more significantly than single agent.

Detailed description: This project is a single-center retrospective cohort study to obtain the biochemical index levels of urinary albumin creatinine ratio, urinary protein creatinine ratio, blood renal function, blood lipids, and blood glucose at the immediate, 3rd, 6th, and 12th month of cohort inclusion in each group of patients.

Eligibility criteria: Inclusion Criteria:

* Age greater than or equal to 18 years
* Clinical diagnosis of type 2 diabetes mellitus
* Immediate urine albumin creatinine ratio greater than 30mg/g
* Signed informed consent and available for follow-up

Exclusion Criteria:

* severe renal insufficiency, i.e. eGFR ≤ 30ml/min/1.75m2
* clinical diagnosis of various acute and chronic urinary tract infections
* combined with various serious infectious diseases
* combined with acute complications of diabetes mellitus
* end-stage malignancy
* pregnancy and lactation

Primary outcomes:
measure: urinary protein changes
timeFrame: 2023.03-2024.03
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University Third Hospital, Beijing, Beijing 100191
state: Beijing
city: Beijing
country: China
facility: Peking University Third Hospital
state: Beijing
Study officials:
References:
Clinical trial NCT05850052: McGrath Videolaryngoscopy and Direct Laryngoscopy Rapid Sequence Intubation
Official title: Comparison of Comparison of McGrath Videolaryngoscopy and Direct Laryngoscopy for Rapid Sequence Intubation: an International, Multicenter Randomized Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Surgery
Lead sponsor: The Cleveland Clinic
Sponsor class: OTHER
First posted: 2023-05-09
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The study seeks to compare the efficacy of conventional direct laryngoscopy using a Macintosh blade with the McGrath videolaryngoscope for rapid sequence endotracheal intubation.

Detailed description: The study aims to conduct a multicenter international trial to enroll a maximum of 800 consenting adults who fall under the American Society of Anesthesiologists (ASA) physical status 1-3 category and require elective non-cardiac surgery necessitating endotracheal intubation with rapid sequence induction for general anesthesia. The study seeks to compare the efficacy of conventional direct laryngoscopy using a Macintosh blade with the McGrath videolaryngoscope for rapid sequence endotracheal intubation.

Eligibility criteria: Inclusion Criteria:

* Elective surgery requiring oral endotracheal intubation for general anesthesia;
* Anticipated extubation in the operating room;
* American Society of Anesthesiologists (ASA) physical status 2-3;
* Age between 18 and 99 years;
* Body Mass index ≥ 40 kg/m2.

Exclusion Criteria:

* Refusal of participation by attending anesthesiologist;
* Indicated rapid sequence induction for any reason including, but not limited to high risk of aspiration
* Indicated fiberoptic awake intubation.

Primary outcomes:
measure: Visualization of the Vocal Cords
timeFrame: From the start time of intubation to time of the end of surgery, up to 12 hours.
Secondary outcomes:
measure: Number of Participants With 1, 2, 3, and 4 Intubation Attempts
timeFrame: From the start time of intubation to time of the end of surgery, up to 12 hours.
measure: Intubation Failure.
timeFrame: From the start time of intubation to time of the end of surgery, up to 12 hours.
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: The University of Health Science, Bakirkoy Dr. Sadi Konuk Education, and Research Hospital,
city: Konya
country: Turkey
facility: The University of Health Science, Konya City Hospital
Study officials:
affiliation: The Cleveland Clinic
name: Kurt Ruetzler, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06059352: Sleep and Central Auditory Processing Disorder in Autism Spectrum Disorder
Official title: Contribution of Central Auditory Processing Disorder (CAPD) to Sleep Disturbances in Autism Spectrum Disorder (ASD)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Central Auditory Processing Disorder
Autism Spectrum Disorder
Sleep Disturbance
Lead sponsor: Loma Linda University
Sponsor class: OTHER
Collaborators: name: Autism Speaks
First posted: 2023-09-28
Enrollment: 100
Sex: ALL
Minimum age (years): 6
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: One hundred school-aged children and adolescents with ASD who are between the ages of 6-17 years old.

Brief summary: The proposed study aims to understand poor sleep as a possible cause to CAPD in children and adolescents with ASD (ASD+) compared to ASD youth without CAPD (ASD-), using both caregiver-report and objective clinician administered measures. Additionally, the study will aim to understand the complex relationship between CAPD, sleep, and other associated phenotypic features of ASD such as executive and psychiatric functioning.

Detailed description: Participation will involve one assessment session approximating 4 hours including administration of neurocognitive and socioemotional measures by trained research staff. The research team then will determine which participants meet CAPD diagnostic criteria for both the SCAN-3 and RGDT tests and assign them to the ASD+ group. Participants not meeting these criteria will be assigned to the ASD- group. Following the assessment visit, all participants will then be asked to wear actigraphy monitors (comparable to overnight polysomnography) regularly for 14 days during nighttime sleep to objectively measure sleep quality.

Eligibility criteria: Inclusion Criteria:

* Have diagnosis of Autism Spectrum Disorder confirmed by the Autism Diagnostic Observation Schedule and the Social Communication Questionnaire, Lifetime Version which will be filled by the parent
* IQ of 50 or higher on the Abbreviated Battery IQ Score

Exclusion Criteria:

* No confirmed diagnosis of Autism Spectrum Disorder
* History of sleep apnea
* History of restless leg syndrome
* History of any neurological disorders (e.g., seizures, tumors, etc.)
* Significant substance use in the past six months
* Inpatient hospitalization in the past three months-period

Primary outcomes:
measure: Sensory Processing Patterns in Children Ages 14 and Below
timeFrame: Through study completion, an average of one year
measure: Sensory Processing Patterns in Children Ages 15 and Above
timeFrame: Through study completion, an average of one year
Secondary outcomes:
Other outcomes:
Locations:
city: Loma Linda
country: United States
facility: Loma Linda University Health
state: California
Study officials:
affiliation: Loma Linda University
name: Aarti Nair, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04161352: Endostar Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III NSCLC
Official title: A Multicenter, Prospective Real World Study on Recombinant Human Endostatin (Endostar) Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III Non-small-cell Lung Cancer
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Unresectable Stage III NSCLC
Lead sponsor: Zhejiang Cancer Hospital
Sponsor class: OTHER
First posted: 2019-11-13
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: the patients with untreated pathologically confirmed inoperable stage III NSCLC, suitable for the treatment of CCRT

Brief summary: The chemoradiotherapy (CCRT) is still a standard treatment for the unresectabl stage III NSCLC.However, prognosis following this treatment is generally poor, with 5-year survival of 15-20%. The result of published HELPER study had showed that Endostar, a kind of angiogenesis agent, in combination with CCRT could improve the efficacy and safety. In order to verify the rusults, the investigators design the current study.

Detailed description: The current study is a observation study in the real world setting. The 500 patients in compliance with Enrollment Criteria will be as the objects of observation. The procedure of study include the period of screening, treating and follow-up. The duration of study is about two and half year. The data entrying will be done by CRC, using the EDC system. CRA will audit the quality of data regularly.

Eligibility criteria: Inclusion Criteria:

* untreated pathologically confirmed inoperable stage III NSCLC according to the 8th edition of the American Joint Committee on Cancer staging system;
* at least one measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST)1.1;
* 18-75 years of age;
* Eastern Cooperative Oncology Group performance status score (ECOG PS) of 0 to 1;
* 10) FEV1\>1.0 L;
* suitable function of bone marrow, liver, kidney and coagulation

Exclusion Criteria:

history of other malignant diseases, uncontrolled hypertension, any contraindications to chemoradiotherapy, pregnancy, breastfeeding or preexisting bleeding diatheses.

-

Primary outcomes:
measure: PFS
timeFrame: 15 months
Secondary outcomes:
measure: OS
timeFrame: 3 years
measure: LRFS
timeFrame: 2 years
measure: DMFS
timeFrame: 2 years
measure: AEs
timeFrame: 3 years
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03004352: Disturbed Blood Flow Induces Endothelial Dysfunction in Severe Chronic Obstructive Pulmonary Disease
Official title: Disturbed Blood Flow Induces Endothelial Dysfunction in Severe Chronic Obstructive Pulmonary Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Obstructive Pulmonary Disease
Lead sponsor: University of Split, School of Medicine
Sponsor class: OTHER
First posted: 2016-12-28
Enrollment: 27
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The aim of the study is to determine if increased retrograde shear would further deteriorate the already impaired vascular function in severe COPD patients.


Eligibility criteria: Inclusion Criteria:

* COPD
* chronic hypoxemia

Exclusion Criteria:

* an acute exacerbation, active respiratory infection or infection of other localisation 6 weeks prior to the visit
* relevant coexisting lung disease such as interstitial lung disease, cancer, renal failure, thromboembolic disease or major cardiovascular event during the previous year
* informed consent not provided or inability to comply with the study protocol

Primary outcomes:
measure: Change from Baseline Brachial Artery Diameter at 10, 20 and 25 minutes
timeFrame: 0,10, 20 and 25 minutes
measure: Change from Baseline Microparticle Count at 20 minutes
timeFrame: 0 and 20 minutes
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06805552: Sarcopenia and Systemic Therapy in HCC
Official title: Prognostic Model of Survival of Patients With Hepatocarcinoma and Sarcopenia Treated With Systemic Therapy
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: HCC - Hepatocellular Carcinoma
Keywords: Hepatocellular Carcinoma
Sarcopenia
HCC systemic therapy
Lead sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Sponsor class: OTHER
Collaborators: name: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
First posted: 2025-02-03
Enrollment: 270
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients affected with Hepatocellular Carcinoma

Brief summary: This is a multi-center, retrospective observational study in patients with liver cancer (HCC) to assess the impact of sarcopenia (muscle loss) on the prognosis, duration, and tolerance of systemic treatment.

Detailed description: The impact of sarcopenia will be assessed 12 months after the start of chemotherapy. Additionally, other factors affecting prognosis will be investigated to develop a specific predictive model for the risk of death at 12 months. Finally, an external validation of this predictive model for the risk of death will be carried out.

Eligibility criteria: Inclusion Criteria:

* Patients aged ≥18 years.
* Diagnosis of hepatocellular carcinoma based on histological and/or radiological results as defined by the European Association for the Study of the Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD). The staging of hepatocellular carcinoma was obtained through contrast-enhanced liver CT and/or MRI.
* Patients with advanced (BCLC-C) or intermediate (BCLC-B) stage hepatocellular carcinoma, or patients with early-stage (BCLC-A) hepatocellular carcinoma who have not responded to previous locoregional ablative treatments and/or liver resection.
* Treatment with TKIs according to the indications and prescription criteria defined by AIFA, with no requirement to reach a minimum treatment period.

Availability of a CT scan performed within no more than 8 weeks prior to the start of TKI therapy.

- Obtaining written informed consent.

Exclusion Criteria:

* None

Primary outcomes:
measure: Prognostic role of Sarcopenia in HCC patient's survival
timeFrame: From January 2008 to April 2021
Secondary outcomes:
measure: Role of Sarcopenia in HCC systemic therapy tolerability
timeFrame: From January 2008 to April 2021
Other outcomes:
Locations:
city: Bologna
country: Italy
facility: IRCCS AOUBO Policlinico di S.Orsola
Study officials:
References:
Clinical trial NCT01125852: Supplementary Angiographic Embolization for Peptic Ulcer Bleeding
Official title: Supplementary Angiographic Embolization for Peptic Ulcer Bleeding: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Peptic Ulcer Hemorrhage
Keywords: Peptic ulcer hemorrhage
Peptic ulcer bleeding
Angiographic embolization
Arterial embolization
Angiography
Lead sponsor: Odense University Hospital
Sponsor class: OTHER
First posted: 2010-05-19
Enrollment: 105
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Peptic ulcer bleeding is a common disorder. Despite optimal endoscopic and medical treatment, there is a high risk of rebleeding and high mortality. In this study the investigators examine whether combined endoscopic haemostasis and angiographic embolization resolves in a better outcome than the traditional use of endoscopic haemostasis alone. The study is a randomised controlled trail.


Eligibility criteria: Inclusion Criteria:

* Clinical signs of upper GI-bleeding
* Endoscopic verified high-risk ulcer (Forrest I-IIb)
* Primary haemostasis achieved

Exclusion Criteria:

* Expected lifetime \< 1 month
* Upper GI-cancer found at endoscopy

Primary outcomes:
measure: Composite Endpoint
timeFrame: Meassured after a week from primary therapeutic endoscopy
Secondary outcomes:
measure: Mortality
timeFrame: 1 month
measure: Rebleeding
timeFrame: 1 month
measure: Blood transfusion
timeFrame: 1 month
measure: Surgical haemostasis
timeFrame: 1 month
measure: Endoscopic/other haemostatic retreatment
timeFrame: 1 month
measure: Duration of hospitalization
timeFrame: Estimated 4 days
measure: Thromboembolic complications
timeFrame: 1 month
Other outcomes:
Locations:
city: Odense
country: Denmark
facility: Odense University Hospital
Study officials:
References:
citation: Laursen SB, Hansen JM, Andersen PE, Schaffalitzky de Muckadell OB. Supplementary arteriel embolization an option in high-risk ulcer bleeding--a randomized study. Scand J Gastroenterol. 2014 Jan;49(1):75-83. doi: 10.3109/00365521.2013.854829. Epub 2013 Nov 21.
Clinical trial NCT03034252: Retrospective Evaluation of Liposarcoma
Official title: Retrospective Evaluation of Liposarcoma
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Survival , Tumor
Lead sponsor: Technical University of Munich
Sponsor class: OTHER
First posted: 2017-01-27
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with Liposarcoma treated at our clinic

Brief summary: Retrospective Evaluation of Survival after Liposarcoma


Eligibility criteria: Inclusion Criteria:

* Patients with Liposarcoma treated surgically at our clinic

Exclusion Criteria:

* N/A

Primary outcomes:
measure: Survival rate
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Munich
country: Germany
facility: Klinikum rechts der Isar
state: Bavaria
Study officials:
affiliation: Klinikum rechts der Isar
name: norbert harrasser
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04828252: Low Level Laser Intervention for Individuals With Knee Osteoarthritis
Official title: The Effects of Low Level Laser Intervention on Muscular Strength for Individuals With Knee Osteoarthritis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Osteoarthritis, Knee
Lead sponsor: National Cheng-Kung University Hospital
Sponsor class: OTHER
First posted: 2021-04-02
Enrollment: 56
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study was to investigate the intervention effects of low level laser for knee OA group


Eligibility criteria: Inclusion Criteria:

* The severity of osteoarthritis was defined by the Kellgren-Lawrence system as grade 2 - grade 3

Exclusion Criteria:

* Uncontrolled hypertension
* Malignant tumor
* Skin cancer
* Pregnant
* Dysesthesia
* Pacemaker inplement
* Cognitive problem
* Fall record within 6 months
* Dysfunction of blood coagulation

Primary outcomes:
measure: Changes of muscular strength of thigh measured by handheld dynamometer
timeFrame: Baseline and after treatment, 8 weeks intervention
Secondary outcomes:
measure: Changes of walking speed measured by the stop watch
timeFrame: Baseline and after treatment, 8 weeks intervention
measure: Changes of stair climbing ability measured by the stop watch
timeFrame: Baseline and after treatment, 8 weeks intervention
measure: Changes of chair stand ability, the stop watch will be used to measure time and investigators count the time that participants complete
timeFrame: Baseline and after treatment, 8 weeks intervention
measure: Changes of dynamic balance ability measured by the stop watch
timeFrame: Baseline and after treatment, 8 weeks intervention
Other outcomes:
measure: Changes of joint range of motion measured by the goniometer
timeFrame: Baseline and after treatment, 8 weeks intervention
Locations:
city: Tainan
country: Taiwan
facility: Department of Physical Therapy, National Cheng-Kung University
Study officials:
affiliation: Department of Physical Therapy, National Cheng-Kung University
name: Cheng-Feng Lin, Ph.D
role: STUDY_CHAIR
References: